Compounds for use in the prevention or treatment of cancer
AssigneesSemmelweis University, Fujimoto Co., Ltd.
InventorsJózsef KNOLL, Ildikó MIKLYA, Péter FERDINANDY, Dezso SCHULER, Zsuzsanna SCHAFF, Sándor ECKHARDT
Life of this patent
Estimating the term…
Abstract
The invention relates to the field of prevention and treatment of cancer, in particular suppression of tumor manifestation. The invention also relates to compounds for use in this field. A novel tumour manifestation suppression (TMS) regulation in a mammalian brain is recognized. The invention relates to compounds, pharmaceutical preparations, in particular medicaments for use in the prevention and treatment of cancer, in particular suppression of tumor manifestation based on said TMS regulation as well as methods for the same.
Claims16
A neuronal activity enhancer compound said compound having general formula II or a pharmaceutically acceptable salt thereof
- wherein said compound is a monoaminergic enhancer compound which enhances impulse propagation mediated release of a monoamine neurotransmitter from monoaminergic neurons in the central nervous system,
- for use in preventing or treating a cancer or a metastasis thereof,
- wherein in formula II
- Q is
- a substituted or unsubstituted bicyclic group which consists of
- a benzene ring and, fused to said benzene ring,
- a saturated or unsaturated five- or six-membered ring which may or may not have one to three, preferably one to two heteroatom(s)
- wherein if Q is substituted,
- said substituent is selected from the group consisting of hydrogen, hydroxyl, C1-4 alkyl, C1-4 alkoxy and halogen, preferably Q is substituted with one or two substituent(s) or is unsubstituted,
- R1 is C1-5 alkyl, preferably C1-4 alkyl, preferably methyl, ethyl or propyl;
- R2 is hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C2-4 alkylcarbonyl, C6-10 aryl or C7-11 arylalkyl;
- R3 is hydrogen, methyl or ethyl.
The method of claim 16 wherein the cancer is a malignant tumor or the cancer selected from the group consisting of carcinomas, sarcomas, leukemias, lymphomas and germinomas, preferably a carcinoma or a sarcoma of the connective tissue.
The method of claim 16 wherein the subject is a warm-blooded animal, preferably a mammal, preferably a human, and wherein preferably the subject is a sexually mature subject, preferably an adult subject.
The method of claim 16 wherein said compound is administered to the subject for at least 1, 2, 3, 5, 6, 8 or 10 months or for at least 1, 2, 3, 4, 5 or 6 years.
A method for treating or suppressing manifestation of a cancer or a metastasis thereof, said method comprising administering to a subject in need thereof a neuronal activity enhancer compound said compound having general formula II or a pharmaceutically acceptable salt thereof
- wherein said compound is a monoaminergic enhancer compound which enhances impulse propagation mediated release of a monoamine neurotransmitter from monoaminergic neurons in the central nervous system,
- wherein in formula II
- Q is
- a substituted or unsubstituted bicyclic group which consists of
- a benzene ring and, fused to said benzene ring,
- a saturated or unsaturated five- or six-membered ring which may or may not have one to three, preferably one to two heteroatom(s)
- wherein if Q is substituted,
- said substituent is selected from the group consisting of hydrogen, hydroxyl, C1-4 alkyl, C1-4 alkoxy and halogen, preferably Q is substituted with one or two substituent(s) or is unsubstituted,
- R1 is C1-5 alkyl, preferably C1-4 alkyl, preferably methyl, ethyl or propyl;
- R2 is hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C2-4 alkylcarbonyl, C6-10 aryl or C7-11 arylalkyl;
- R3 is hydrogen, methyl or ethyl.
Dependencies are inferred from the claim text.